Veligrotug |
ZB-001; VRDN-001; AVE-1642 |
Phase 3 Clinical |
Viridian Therapeutics Inc |
Solid tumours; Graves Ophthalmopathy; Multiple Myeloma; Breast Neoplasms |
Details
|
Teprotumumab biosimilar(Innovent) |
IBI-311 |
Phase 3 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Graves Ophthalmopathy |
Details
|
Ganitumab |
AMG-479 |
Phase 3 Clinical |
Amgen Inc |
Breast Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms; Lymphoma; Rhabdomyosarcoma, Alveolar; Lung Neoplasms; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Prostatic Neoplasms; Sarcoma; Sarcoma, Ewing; Bone metastases; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Colonic Neoplasms; Rectal Neoplasms; Carcinoid Tumor; Rhabdomyosarcoma, Embryonal; Ovarian Neoplasms; Rhabdomyosarcoma; Solid tumours; Intestinal Neoplasms |
Details
|
Linsitinib |
OSI-906; ASP-7487; OSI-906AA |
Phase 3 Clinical |
Astellas Pharma Inc, National Cancer Institute |
Multiple Myeloma; Paraganglioma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Orbital Diseases; Eye Diseases; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Exophthalmos; Breast Neoplasms; Prostatic Neoplasms; Sarcoma, Ewing; Adrenocortical Carcinoma; Thyroid Diseases; Graves Ophthalmopathy; Endocrine System Diseases; Skin Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Hashimoto Disease; Head and Neck Neoplasms; Ovarian Neoplasms; Carney Complex; Liver Neoplasms; Solid tumours; Chondrosarcoma |
Details
|
Conteltinib |
CT-707; SY-707 |
Phase 3 Clinical |
Shouyao Holding (Beijing) Co Ltd, Beijing Centaurus Biopharma Co Ltd |
Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
FPI-1434 |
[225Ac]-FPI-1434; FPX-01 |
Phase 2 Clinical |
Fusion Pharma |
Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Neoplasms; Adrenocortical Carcinoma; Uveal melanoma; Breast Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms |
Details
|
Dalotuzumab |
h7C-10; MK-0646; F-50-035 |
Phase 2 Clinical |
Pierre Fabre Group |
Solid tumours; Rectal Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Neuroendocrine Tumors; Multiple Myeloma; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung |
Details
|
CT-102 |
CT-102 |
Phase 2 Clinical |
Hangzhou Tianlong Pharmaceutical Co Ltd, Institute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences |
Liver Neoplasms; Carcinoma, Hepatocellular |
Details
|
lonigutamab ugodotin |
W-0101 |
Phase 2 Clinical |
Pierre Fabre Group |
Solid tumours |
Details
|
Mecasermin Rinfabate |
OHB-607; SHP-607; HGT-ROP-001; rhIGF-I/rhIGFBP-3; TAK-607 |
Phase 2 Clinical |
Insmed |
Noonan Syndrome; Failure to Thrive; Cerebral Intraventricular Hemorrhage; Bronchopulmonary Dysplasia; Myotonic Dystrophy; Retinopathy of Prematurity; Muscular Dystrophies; Laron Syndrome |
Details
|
MHB018A |
|
Phase 2 Clinical |
Minghui Pharmaceutical (Hangzhou) Co Ltd |
Graves Ophthalmopathy |
Details
|
Lonigutamab |
VB-421 |
Phase 2 Clinical |
Pierre Fabre Group |
Graves Ophthalmopathy |
Details
|
Cixutumumab |
A-12; IMC-A12; LY-3012217; NSC-742460 |
Phase 2 Clinical |
Eli Lilly And Company |
Gastrinoma; Adenocarcinoma, Bronchiolo-Alveolar; Gliosarcoma; Colorectal Neoplasms; Neuroblastoma; Medullary thyroid cancer (MTC); Chondrosarcoma, Extraskeletal Myxoid; Retinoblastoma; Neurofibrosarcoma; Brain Stem Neoplasms; Lymphoma, Mantle-Cell; Breast Neoplasms; Osteosarcoma; Prostatic Neoplasms; Sarcoma; Sarcoma, Ewing; Liposarcoma; Esophageal adenocarcinoma; Neuroectodermal Tumors, Primitive, Peripheral; Adenocarcinoma; Melanoma; Paraganglioma; Breast Neoplasms, Male; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Sarcoma, Alveolar Soft Part; Adrenocortical Carcinoma; Rhabdomyosarcoma, Alveolar; Carcinoma, Neuroendocrine; Glioma; Esophageal Squamous Cell Carcinoma; Hemangiopericytoma; Lung Neoplasms; Pinealoma; Rectal Neoplasms; Carcinoma, Merkel Cell; Stomach Neoplasms; Hemangiosarcoma; Insulinoma; Hepatoblastoma; Esophageal Neoplasms; Mesenchymoma; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma, Embryonal; Carcinoma; Fibrosarcoma; Kidney Neoplasms; Liver Neoplasms; Head and Nec |
Details
|
Picropodophyllin |
PPP; AXL-1717; NSC-36407 |
Phase 2 Clinical |
Axelar Ab |
Astrocytoma; Carcinoma, Non-Small-Cell Lung |
Details
|
NNC0268-0965 |
NNC0268-0965 |
Phase 1 Clinical |
Novo Nordisk A/S |
Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 |
Details
|
IGF-1 receptor oligodeoxynucleotide-based immunotherapy (Thomas Jefferson University) |
|
Phase 1 Clinical |
Sidney Kimmel Cancer Center |
Glioma |
Details
|
Insulin-Like Growth Factor 1 (Wright State Physicians) |
|
Phase 1 Clinical |
Wright State Physicians |
Nasolabial fold wrinkles; Burns; Sunburn |
Details
|
SAR-446159 |
ABL-301; SAR-446159 |
Phase 1 Clinical |
Abl Bio Inc |
Parkinson Disease |
Details
|
VRDN-003 |
VRDN-003 |
Phase 1 Clinical |
Viridian Therapeutics Inc |
Graves Ophthalmopathy |
Details
|
VRDN-002 |
VRDN-002 |
Phase 1 Clinical |
Viridian Therapeutics Inc |
Graves Ophthalmopathy |
Details
|
LX-101 (Lirum Therapeutics) |
765IGF-MTX; IGF/MTX |
Phase 1 Clinical |
Lirum Therapeutics Inc |
Head and Neck Neoplasms; Anemia, Refractory, with Excess of Blasts; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Neoplasms; Graves Ophthalmopathy; Breast Neoplasms; Brain Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Melanoma; Gastrointestinal Neoplasms |
Details
|
ZB-011 |
ZB-011; ZB011 |
Phase 1 Clinical |
Viridian Therapeutics Inc |
Graves Ophthalmopathy |
Details
|
Teprotumumab(Zhejiang Boxiao Bio-pharma) |
|
Phase 1 Clinical |
Zhejiang Boxiao Bio-pharmaceutical Co Ltd |
Graves Ophthalmopathy |
Details
|
PHP-1003 |
PHP-1003; PHP1003 |
Phase 1 Clinical |
Suzhou Pulekang Pharmaceutical Technology Co Ltd |
Graves Ophthalmopathy |
Details
|
124I-CPD-1023-figitumumab |
124I-CPD-1028; 125I-CPD-1028; CPD-1028-[124I]; CPD-1028-[125I]; FPX-1028 |
Phase 1 Clinical |
Fusion Pharma |
Neoplasms |
Details
|
Veligrotug |
ZB-001; VRDN-001; AVE-1642 |
Phase 3 Clinical |
Viridian Therapeutics Inc |
Solid tumours; Graves Ophthalmopathy; Multiple Myeloma; Breast Neoplasms |
Details
|
Teprotumumab biosimilar(Innovent) |
IBI-311 |
Phase 3 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Graves Ophthalmopathy |
Details
|
Ganitumab |
AMG-479 |
Phase 3 Clinical |
Amgen Inc |
Breast Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms; Lymphoma; Rhabdomyosarcoma, Alveolar; Lung Neoplasms; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Prostatic Neoplasms; Sarcoma; Sarcoma, Ewing; Bone metastases; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Colonic Neoplasms; Rectal Neoplasms; Carcinoid Tumor; Rhabdomyosarcoma, Embryonal; Ovarian Neoplasms; Rhabdomyosarcoma; Solid tumours; Intestinal Neoplasms |
Details
|
Linsitinib |
OSI-906; ASP-7487; OSI-906AA |
Phase 3 Clinical |
Astellas Pharma Inc, National Cancer Institute |
Multiple Myeloma; Paraganglioma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Orbital Diseases; Eye Diseases; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Exophthalmos; Breast Neoplasms; Prostatic Neoplasms; Sarcoma, Ewing; Adrenocortical Carcinoma; Thyroid Diseases; Graves Ophthalmopathy; Endocrine System Diseases; Skin Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Hashimoto Disease; Head and Neck Neoplasms; Ovarian Neoplasms; Carney Complex; Liver Neoplasms; Solid tumours; Chondrosarcoma |
Details
|
Conteltinib |
CT-707; SY-707 |
Phase 3 Clinical |
Shouyao Holding (Beijing) Co Ltd, Beijing Centaurus Biopharma Co Ltd |
Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
FPI-1434 |
[225Ac]-FPI-1434; FPX-01 |
Phase 2 Clinical |
Fusion Pharma |
Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Neoplasms; Adrenocortical Carcinoma; Uveal melanoma; Breast Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms |
Details
|
Dalotuzumab |
h7C-10; MK-0646; F-50-035 |
Phase 2 Clinical |
Pierre Fabre Group |
Solid tumours; Rectal Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Neuroendocrine Tumors; Multiple Myeloma; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung |
Details
|
CT-102 |
CT-102 |
Phase 2 Clinical |
Hangzhou Tianlong Pharmaceutical Co Ltd, Institute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences |
Liver Neoplasms; Carcinoma, Hepatocellular |
Details
|
lonigutamab ugodotin |
W-0101 |
Phase 2 Clinical |
Pierre Fabre Group |
Solid tumours |
Details
|
Mecasermin Rinfabate |
OHB-607; SHP-607; HGT-ROP-001; rhIGF-I/rhIGFBP-3; TAK-607 |
Phase 2 Clinical |
Insmed |
Noonan Syndrome; Failure to Thrive; Cerebral Intraventricular Hemorrhage; Bronchopulmonary Dysplasia; Myotonic Dystrophy; Retinopathy of Prematurity; Muscular Dystrophies; Laron Syndrome |
Details
|
MHB018A |
|
Phase 2 Clinical |
Minghui Pharmaceutical (Hangzhou) Co Ltd |
Graves Ophthalmopathy |
Details
|
Lonigutamab |
VB-421 |
Phase 2 Clinical |
Pierre Fabre Group |
Graves Ophthalmopathy |
Details
|
Cixutumumab |
A-12; IMC-A12; LY-3012217; NSC-742460 |
Phase 2 Clinical |
Eli Lilly And Company |
Gastrinoma; Adenocarcinoma, Bronchiolo-Alveolar; Gliosarcoma; Colorectal Neoplasms; Neuroblastoma; Medullary thyroid cancer (MTC); Chondrosarcoma, Extraskeletal Myxoid; Retinoblastoma; Neurofibrosarcoma; Brain Stem Neoplasms; Lymphoma, Mantle-Cell; Breast Neoplasms; Osteosarcoma; Prostatic Neoplasms; Sarcoma; Sarcoma, Ewing; Liposarcoma; Esophageal adenocarcinoma; Neuroectodermal Tumors, Primitive, Peripheral; Adenocarcinoma; Melanoma; Paraganglioma; Breast Neoplasms, Male; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Sarcoma, Alveolar Soft Part; Adrenocortical Carcinoma; Rhabdomyosarcoma, Alveolar; Carcinoma, Neuroendocrine; Glioma; Esophageal Squamous Cell Carcinoma; Hemangiopericytoma; Lung Neoplasms; Pinealoma; Rectal Neoplasms; Carcinoma, Merkel Cell; Stomach Neoplasms; Hemangiosarcoma; Insulinoma; Hepatoblastoma; Esophageal Neoplasms; Mesenchymoma; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma, Embryonal; Carcinoma; Fibrosarcoma; Kidney Neoplasms; Liver Neoplasms; Head and Nec |
Details
|
Picropodophyllin |
PPP; AXL-1717; NSC-36407 |
Phase 2 Clinical |
Axelar Ab |
Astrocytoma; Carcinoma, Non-Small-Cell Lung |
Details
|
NNC0268-0965 |
NNC0268-0965 |
Phase 1 Clinical |
Novo Nordisk A/S |
Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 |
Details
|
IGF-1 receptor oligodeoxynucleotide-based immunotherapy (Thomas Jefferson University) |
|
Phase 1 Clinical |
Sidney Kimmel Cancer Center |
Glioma |
Details
|
Insulin-Like Growth Factor 1 (Wright State Physicians) |
|
Phase 1 Clinical |
Wright State Physicians |
Nasolabial fold wrinkles; Burns; Sunburn |
Details
|
SAR-446159 |
ABL-301; SAR-446159 |
Phase 1 Clinical |
Abl Bio Inc |
Parkinson Disease |
Details
|
VRDN-003 |
VRDN-003 |
Phase 1 Clinical |
Viridian Therapeutics Inc |
Graves Ophthalmopathy |
Details
|
VRDN-002 |
VRDN-002 |
Phase 1 Clinical |
Viridian Therapeutics Inc |
Graves Ophthalmopathy |
Details
|
LX-101 (Lirum Therapeutics) |
765IGF-MTX; IGF/MTX |
Phase 1 Clinical |
Lirum Therapeutics Inc |
Head and Neck Neoplasms; Anemia, Refractory, with Excess of Blasts; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Neoplasms; Graves Ophthalmopathy; Breast Neoplasms; Brain Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Melanoma; Gastrointestinal Neoplasms |
Details
|
ZB-011 |
ZB-011; ZB011 |
Phase 1 Clinical |
Viridian Therapeutics Inc |
Graves Ophthalmopathy |
Details
|
Teprotumumab(Zhejiang Boxiao Bio-pharma) |
|
Phase 1 Clinical |
Zhejiang Boxiao Bio-pharmaceutical Co Ltd |
Graves Ophthalmopathy |
Details
|
PHP-1003 |
PHP-1003; PHP1003 |
Phase 1 Clinical |
Suzhou Pulekang Pharmaceutical Technology Co Ltd |
Graves Ophthalmopathy |
Details
|
124I-CPD-1023-figitumumab |
124I-CPD-1028; 125I-CPD-1028; CPD-1028-[124I]; CPD-1028-[125I]; FPX-1028 |
Phase 1 Clinical |
Fusion Pharma |
Neoplasms |
Details
|